Document Detail


Some aspects of hemostasis in CAPD patients treated with erythropoietin.
MedLine Citation:
PMID:  12424426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Bleeding diathesis and simultaneous thrombotic complications may be seen in dialyzed patients. Erythropoietin may shift the precarious balance of the hemostatic system towards thrombosis. Thrombin activatable fibrinolysis inhibitor (TAFI) is a key protein linking coagulation and fibrinolysis. METHODS: The effects of 3-month erythropoietin treatment on some hemostatic parameters--TAFI, fibrinolytic activity index (FAI), markers of ongoing coagulation (thrombin-antithrombin complexes and prothrombin fragments 1 + 2), marker of ongoing fibrinolysis (plasmin-antiplasmin complexes) and marker of endothelial cell injury (thrombomodulin)--were studied in 17 patients on continuous ambulatory peritoneal dialysis (CAPD). Patients on CAPD not treated with rHuEPO were also studied. Healthy volunteers served as a control group. 2,000 U erythropoietin was given subcutaneously three times a week. Commercially available kits were used to determine hemostatic parameters. RESULTS: All the hemostatic parameters studied were significantly higher in CAPD patients when compared to the control group. All these hemostatic parameters except the plasmin-antiplasmin complexes did not differ significantly between patients before rHuEPO therapy and patients without rHuEPO. Erythropoietin therapy resulted in a significant decrease in plasmin-antiplasmin complexes, a significant rise in FAI after 3 months of drug administration, and a tendency to decrease the TAFI concentration and activity (after 1 month, p = 0.11 and p = 0.10, respectively; after 3 months p = 0.07 and p = 0.06, respectively). Treatment with erythropoietin did not affect platelet count, prothrombin time, activated partial thromboplastin time, cholesterol, triglycerides, fibrinogen, total protein, albumin, serum iron, ferritin, fibronectin, pH, bicarbonates, creatinine, and urea. Hemoglobin and hematocrit increased significantly after 1 month of the therapy. CONCLUSION: Short-term treatment with erythropoietin seems to minimally affect hemostasis in CAPD patients.
Authors:
Jolanta Małyszko; Ewa Suchowierska; Jacek S Małyszko; Michał Myśliwiec
Related Documents :
21358306 - Epidemiology of spondyloarthritis in brazil.
6083956 - On the clinical significance of acquired antithrombin deficiency.
3088986 - Ddavp in acquired von willebrand syndrome associated with multiple myeloma.
9184386 - High prevalence of elevated factor viii levels in patients referred for thrombophilia s...
8797486 - Prospective evaluation of mri lumbosacral nerve root enhancement in acute guillain-barr...
10436296 - High incidence of transiently appearing complement-sensitive bone marrow precursor cell...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Kidney & blood pressure research     Volume:  25     ISSN:  1420-4096     ISO Abbreviation:  Kidney Blood Press. Res.     Publication Date:  2002  
Date Detail:
Created Date:  2002-11-08     Completed Date:  2003-05-29     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9610505     Medline TA:  Kidney Blood Press Res     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  240-4     Citation Subset:  IM    
Copyright Information:
Copyright 2002 S. Karger AG, Basel
Affiliation:
Department of Nephrology and Internal Medicine, Medical Academy of Białystok, Zurawia 14, PL-15-540 Białystok, Poland. jolmal@poczta.onet.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biological Markers
Blood Coagulation / drug effects
Blood Coagulation Tests
Body Mass Index
Erythrocyte Count
Erythropoietin, Recombinant / therapeutic use*
Female
Fibrinolysin / biosynthesis
Fibrinolysis
Hematocrit
Hemostasis / drug effects,  physiology*
Humans
Male
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory / adverse effects*
Thrombomodulin / metabolism
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Erythropoietin, Recombinant; 0/Thrombomodulin; EC 3.4.21.7/Fibrinolysin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunoadsorption and plasma exchange in pregnancy.
Next Document:  G-protein beta-3-subunit and eNOS gene polymorphism in transplant recipients with long-term renal gr...